{
    "nct_id": "NCT06233331",
    "official_title": "Phase I Dose Escalation Study of the Use of ACU-D1, a Topical Proteasome Inhibitor in HPV Associated Vulvar and Perianal Lesions in People With HIV",
    "inclusion_criteria": "* Age 21 years and older\n* HIV-infected\n* Able to provide informed consent\n* Biopsy-proven HSIL disease of the vulvar and perianal region with a total disease volume of 3 cm or greater\n* Combined antiretrovirals (cART) adherence\n* CD4 count > 200 cells/ml\n* Sustained undetectable viral load for â‰¥ 3 months\n* If applicable, on reliable birth control such as combined oral contraceptive pills (OCP), bilateral tubal ligation (BTL), a long-acting reversible contraceptive, or Depo-Provera (birth control shot)\n* Willingness to conform to study requirements\n* Reliable follow-up and contact information\n* No risk factors or clinical suspicion for micro-invasive disease and absence of medical condition that interferes with the conduct of the study in the investigator's opinion\nHealthy volunteers allowed\nMust have minimum age of 21 Years",
    "exclusion_criteria": "* Currently pregnant (confirmed by collecting urine for HCG pregnancy test) or lactating",
    "miscellaneous_criteria": ""
}